1. Field of the Invention
The present invention relates to tissue-supporting medical devices, and more particularly to expandable, non-removable devices that are implanted within a bodily lumen of a living animal or human to support the organ and maintain patency.
2. Summary of the Related Art
In the past, permanent or biodegradable devices have been developed for implantation within a body passageway to maintain patency of the passageway. These devices are typically introduced percutaneously, and transported transluminally until positioned at a desired location. These devices are then expanded either mechanically, such as by the expansion of a mandrel or balloon positioned inside the device, or expand themselves by releasing stored energy upon actuation within the body. Once expanded within the lumen, these devices, called stents, become encapsulated within the body tissue and remain a permanent implant.
Known stent designs include monofilament wire coil stents (U.S. Pat. No. 4,969,458); welded metal cages (U.S. Pat. Nos. 4,733,665 and 4,776,337); and, most prominently, thin-walled metal cylinders with axial slots formed around the circumference (U.S. Pat. Nos. 4,733,665, 4,739,762, and 4,776,337). Known construction materials for use in stents include polymers, organic fabrics and biocompatible metals, such as, stainless steel, gold, silver, tantalum, titanium, and shape memory alloys such as Nitinol.
U.S. Pat. Nos. 4,733,665, 4,739,762, and 4,776,337 disclose expandable and deformable interluminal vascular grafts in the form of n-walled tubular members with axial slots allowing the members to be expanded radially outwardly into contact with a body passageway. After insertion, the tubular members are mechanically expanded beyond their elastic limit and thus permanently fixed within the body. The force required to expand these tubular stents is proportional to the thickness of the wall material in a radial direction. To keep expansion forces within acceptable levels for use within the body (e.g., 5-10 atm), these designs must use very thin-walled materials (e.g., stainless steel tubing with 0.0025 inch thick walls). However, materials this thin are not visible on conventional fluoroscopic and x-ray equipment and it is therefore difficult to place the stents accurately or to find and retrieve stents that subsequently become dislodged and lost in the circulatory system.
Further, many of these thin-walled tubular stent designs employ networks of long, slender struts whose width in a circumferential direction is two or more times greater than their thickness in a radial direction. When expanded, these struts are frequently unstable, that is, they display a tendency to buckle, with individual struts twisting out of plane. Excessive protrusion of these twisted struts into the bloodstream has been observed to increase turbulence, and thus encourage thrombosis. Additional procedures have often been required to attempt to correct this problem of buckled smuts. For example, after initial stent implantation is determined to have caused buckling of struts, a second, high-pressure balloon (e.g., 12 to 18 atm) would be used to attempt to drive the twisted struts her into the lumen wall. These secondary procedures can be dangerous to the patient due to the risk of collateral damage to the lumen wall.
Many of the known stents display a large elastic recovery, known in the field as “recoil,” after expansion inside a lumen. Large recoil necessitates over-expansion of the stent during implantation to achieve the desired final diameter. Over-expansion is potentially destructive to the lumen tissue. Known stents of the type described above experience recoil of up to about 6 to 12% from maximum expansion.
Large recoil also makes it very difficult to securely crimp most known stents onto delivery catheter balloons. As a result, slippage of stents on balloons during interlumenal transportation, final positioning, and implantation has been an ongoing problem. Many ancillary stent securing devices and techniques have been advanced to attempt to compensate for this basic design problem. Some of the stent securing devices include collars and sleeves used to secure the stent onto the balloon.
Another problem with known stent designs is non-uniformity in the geometry of the expanded stent. Non-uniform expansion can lead to non-uniform coverage of the lumen wall creating gaps in coverage and inadequate lumen support. Further, over expansion in some regions or cells of the stent can lead to excessive material strain and even failure of stent features. This problem is potentially worse in low expansion force stents having smaller feature widths and thicknesses in which manufacturing variations become proportionately more significant. In addition, a typical delivery catheter for use in expanding a stent includes a balloon folded into a compact shape for catheter insertion. The balloon is expanded by fluid pressure to unfold the balloon and deploy the stent. This process of unfolding the balloon causes uneven stresses to be applied to the stent during expansion of the balloon due to the folds causing the problem non-uniform stunt expansion.
U.S. Pat. No. 5,545,210 discloses a thin-walled tubular stent geometrically similar to those discussed above, but constructed of a nickel-titanium shape memory alloy (“Nitinol”). This design permits the use of cylinders with thicker walls by making use of the lower yield stress and lower elastic modulus of martensitic phase Nitinol alloys. The expansion force required to expand a Nitinol stent is less than that of comparable thickness stainless steel stents of a conventional design. However, the “recoil” problem after expansion is significantly greater with Nitinol than with other materials. For example, recoil of a typical design Nitinol stent is about 9%. Nitinol is also more expensive, and more difficult to fabricate and machine than other stent materials, such as stainless steel.
All of the above stents share a critical design property: in each design, the features that undergo permanent deformation during stent expansion are prismatic, i.e., the cross sections of these features remain constant or change very gradually along their entire active length. To a first approximation, such features deform under transverse stress as simple beams with fixed or guided ends: essentially, the features act as a leaf springs. These leaf spring like structures are ideally suited to providing large amounts of elastic deformation before permanent deformation commences. This is exactly the opposite of ideal stent behavior. Further, the force required to deflect prismatic stent struts in the circumferential direction during stent expansion is proportional to the square of the width of the strut in the circumferential direction. Expansion forces thus increase rapidly with strut width in the above stent designs. Typical expansion pressures required to expand known stents are between about 5 and 10 atmospheres. These forces can cause substantial damage to tissue if misapplied.
Another stent described in PCT publication number WO 96/29028 uses struts with relatively weak portions of locally-reduced cross sections which on expansion of the stent act to concentrate deformation at these areas. However, as discussed above non-uniform expansion is even more of a problem when smaller feature widths and thicknesses are involved because manufacturing variations become proportionately more significant. The locally-reduced cross section portions described in his document are formed by pairs of circular holes. The shape of the locally-reduced cross section portions undesirably concentrates the plastic strain at the narrowest portion. This concentration of plastic strain without any provision for controlling the level of plastic stain makes the stent highly vulnerable to failure.
In view of the drawbacks of the prior art stents, it would be advantageous to be able to expand a stent with an expansion force at a low level independent of choice of stent materials, material thickness, or strut dimensions.
It would further be advantageous to have a tissue-supporting device that permits a choice of material thickness that could be viewed easily on conventional fluoroscopic equipment for any material.
It would also be advantageous to have a tissue-supporting device that is inherently stable during expansion, thus eliminating buckling and twisting of structural features during stent deployment.
It would also be desirable to control strain to a desired level which takes advantage of work hardening without approaching a level of plastic strain at which failure may occur.
In addition, it would be advantageous to have a tissue-supporting device with minimal elastic recovery, or “recoil” of the device after expansion.
It would be advantageous to have a tissue supporting device that can be securely crimped to the delivery catheter without requiring special tools, techniques, or ancillary clamping features.
It would further be advantageous to have a tissue-supporting device that has improved resistance to compressive forces (improved crush strength) after expansion.
It would also be advantageous to have a tissue-supporting device that achieves all the above improvements with minimal foreshortening of the overall stent length during expansion.
The present invention addresses several important problems in expandable medical device design including: high expansion force requirements; lack of radio-opacity in thin-walled stents; buckling and twisting of stent features during expansion; poor crimping properties; and excessive elastic recovery (“recoil”) after implantation. The invention also provides benefits of improved resistance to compressive forces after expansion, control of the level of plastic strain, and low axial shortening during expansion. Some embodiments of the invention also provide improved uniformity of expansion by limiting a maximum geometric deflection between struts. The invention may also incorporate sites for the inclusion of beneficial agent delivery.
The invention involves the incorporation of stress/strain concentration features or “ductile hinges” at selected points in the body of an expandable cylindrical medical device. When expansion forces are applied to the device as a whole, these ductile hinges concentrate expansion stresses and strains in small, well-defined areas while limiting strut deflection and plastic strain to specified levels.
In accordance with one aspect of the present invention, an expandable medical device includes a plurality of elongated beams having a substantially constant beam cross sectional area along a en length. The plurality of elongated beams are joined together to form a substantially cylindrical device which is expandable from a cylinder having a first diameter to a cylinder having a second diameter. A plurality of ductile hinges connect the plurality of beams together in the substantially cylindrical device. The ductile hinges have a substantially constant hinge-cross sectional area along a substantial portion of a hinge length. The hinge cross sectional area is smaller than the beam cross sectional area such that as the device is expanded from the first diameter to the second diameter the ductile hinges experience plastic deformation while the beams are not plastically deformed.
In accordance with a further aspect of the invention, an expandable medical device includes a cylindrical tube, and a plurality of axial slots formed in the cylindrical tube in a staggered arrangement to define a network of elongated struts, wherein each of the elongated struts are axially displaced from adjacent struts. A plurality of ductile hinges are formed between the elongated struts. The ductile hinges allow the cylindrical tube to be expanded or compressed from a first diameter to a second diameter by deformation of the ductile hinges. The ductile hinges are asymmetrically configured to reach a predetermined strain level upon a first percentage expansion and to reach the predetermined strain level upon a second percentage of compression, wherein the first percentage is larger than the second percentage.
In accordance with another aspect of the present invention, an expandable medical device includes a plurality of elongated beams having a substantially constant beam cross sectional area along a beam length. A plurality of ductile hinges connect the plurality of beams together in a substantially cylindrical device which is expandable or compressible from a first diameter to a second diameter by plastic deformation of the ductile hinges. A plurality of deflection limiting members are positioned at a plurality of the ductile hinges which limit the deflection at the ductile hinges.
The invention will now be described in greater detail with reference to the preferred embodiments illustrated in the accompanying drawings, in which like elements bear like reference numerals, and wherein:
a-d are perspective views of ductile hinges according to several variations of the invention;
e is a side view of another embodiment of a ductile hinge;
a and 4b are an isometric view and an enlarged side view of a tissue-supporting device in accordance with an alternative embodiment of the invention;
a-c are perspective, side, and cross-sectional views of an idealized ductile hinge for purposes of analysis;
d is a stress/strain curve for the idealized ductile hinge;
a and 9b are enlarged side views of ductile hinges in initial and expanded positions with shortened struts to illustrate axial contraction relationships; and
With reference to the drawings and the discussion, the width of any feature is defined as its dimension in the circumferential direction of the cylinder. The length of any feature is defined as its dimension in the axial direction of the cylinder. The thickness of any feature is defined as the wall thickness of the cylinder.
The presence of the ductile hinges 32 allows all of the remaining features in the tissue supporting device to be increased in width or the circumferentially oriented component of their respective rectangular moments of inertia—thus greatly increasing the strength and rigidity of these features. The net result is that elastic, and then plastic deformation commence and propagate in the ductile hinges 32 before other structural elements of the device undergo any significant elastic deformation. The force required to expand the tissue supporting device 20 becomes a function of the geometry of the ductile hinges 32, rather than the device structure as a whole, and arbitrarily small expansion forces can be specified by changing hinge geometry for virtually any material wall thickness. In particular, wall thicknesses great enough to be visible on a fluoroscope can be chosen for any material of interest.
In order to get minimum recoil, the ductile hinges 32 should be designed to operate well into the plastic range of the material, and relatively high local strain-curvatures are developed. When these conditions apply, elastic curvature is a very small fraction of plastic or total curvature, and thus when expansion forces are relaxed, the percent change in hinge curvature is very small. When incorporated into a strut network designed to take maximum advantage of this effect, the elastic springback, or “recoil,” of the overall stent structure is minimized.
In the embodiment of
Yield in ductile hinges at very low gross radial deflections also provides the superior crimping properties displayed by the ductile hinge-based designs. When a tissue supporting device is crimped onto a folded catheter balloon, very little radial compression of the device is possible since the initial fit between balloon and device is already snug. Most stents simply rebound elastically after such compression, resulting in very low clamping forces and the attendant tendency for the stent to slip on the balloon. Ductile hinges, however, sustain significant plastic deformation even at the low deflections occurring during crimping onto the balloon, and therefore a device employing ductile hinges displays much higher clamping forces. The ductile hinge designs according to the present invention may be securely crimped onto a balloon of a delivery catheter by hand or by machine without the need for auxiliary retaining devices commonly used to hold known stents in place.
The geometric details of the stress/strain concentration features or ductile hinges 32 can be varied greatly to tailor the exact mechanical expansion properties to those required in a specific application. The most obvious and straightforward ductile hinges are formed by slots or notches with rounded roots, as in
a shows a ductile hinge 36 formed by a pair of opposed circular grooves 38, 40. According to this embodiment the circumferential slot 26 has semicircular ends 38 having a radius of curvature r. Outer semicircular grooves 40 opposed the semicircular ends 38 and also have a radius of curvature r.
Generally, the ductile hinges 36 of the embodiment of
For smaller deflection, this very high strain concentration at the bisecting plane is acceptable, and in some cases, useful. For stent crimping purposed, for example, it is desirable to generate relatively large plastic deformations at very small deflection angles.
As a practical matter, however, strut deflection angles for device expansion are often in the 25′ to 45′ range. At these angles, strain at the root or bisecting plane of concave ductile hinge features can easily exceed the 50 to 60% elongation-to-failure of 316L stainless steel, one of the most ductile stent materials. Deflection limiting features which will be described further below limit the geometric deflection of struts, but these features do not in themselves affect the propagation pattern of plastic deformation in a given ductile hinge design. For concave ductile hinges at large bend angles, very high strain concentrations remain. Scanning electron micrographs have confirmed this analysis.
In many engineering applications, it is desirable to limit the amount of strain, or “cold-work,” in a material to a specified level in order to optimize material properties and to assure safe operation. For example, in medical applications it is desirable to limit the amount of cold-work in 316L stainless steel to about 30%. At this level, the strength of the material is increased, while the material strain is still well below the failure range. Ideally, therefore, a safe and effective ductile hinge should not simply limit gross deflection, but reliably limit material strain to a specified level.
b shows a simple ductile hinge design that allows material strain to be limited to some specified level. The ductile hinge of
One of the key concepts in
d shows a ductile hinge 60 in a cylindrical wire 62 for incorporating into wire-form tissue-supporting device. The ductile hinge 60 is formed by a reduced diameter portion of the wire 62. Again, it is important that the ductile hinge have a substantially constant width over a portion of its length in order to provide strain control. Preferably, the ductile hinge is prismatic over a portion of its length. Maximum material strain can be varied by adjusting the hinge length. The ductile hinges of the present invention have a constant or substantially constant width over at least ⅓ of the ductile hinge length, and preferably over at least ½ of the ductile hinge length.
e shows an asymmetric ductile hinge 63 that produces different strain versus deflection-angle functions in expansion and compression. Each of the ductile hinges 64 is formed between a convex surface 68 and a concave surface 69. The ductile hinge 64 according to a preferred embodiment essentially takes the form of a small, prismatic curved beam having a substantially constant cross section. However, a thickness of the curved ductile hinge 64 may vary somewhat as long as the ductile hinge width remains constant along a portion of the hinge length. The width of the curved beam is measure along the radius of curvature of the beam. This small curved beam is oriented such that the smaller concave surface 69 is placed in tension in the device crimping direction, while the larger convex surface 68 of the ductile hinges is placed in tension in the device expansion direction. Again, there is no local minimum width of the ductile hinge 64 along the (curved) ductile hinge axis, and no concentration of material strain. During device expansion tensile strain will be distributed along the convex surface 68 of the hinge 64 and maximum expansion will be limited by the angle of the walls of the concave notch 69 which provide a geometric deflection limiting feature. Maximum tensile strain can therefore be reliably limited by adjusting the initial length of the convex arc shaped ductile hinge 64 over which the total elongation is distributed.
The ductile hinges illustrated in
An alternative embodiment of a tissue supporting device 80 is illustrated in
The notches 94 each have two opposed angled walls 96 which function as a stop to limit geometric deflection of the ductile hinge, and thus limit maximum device expansion. As the cylindrical tubes 82 are expanded and bending, occurs at the ductile hinges 90, the angled side walls 96 of the notches 94 move toward each other. Once the opposite side walls 96 of a notch come into contact with each other, they resist farther expansion of the particular ductile hinge causing further expansion to occur at other sections of the tissue supporting device. This geometric deflection limiting feature is particularly useful where uneven expansion is caused by either variations in the tissue supporting device 80 due to manufacturing tolerances or uneven balloon expansion.
The tissue supporting device 20, 80 according to the present invention may be formed of any ductile material, such as steel, gold, silver, tantalum, titanium, Nitinol, other shape memory alloys, other metals, or even some plastics. One preferred method for making the tissue supporting device 20, 80 involves forming a cylindrical tube and then laser cutting the slots 22, 26, 86, 92 and notches 94 into the tube. Alternatively, the tissue supporting device may be formed by electromachining, chemical etching followed by rolling and welding, or any other known method.
The design and analysis of stress/strain concentration for ductile hinges, and stress/strain concentration features in general, is complex. For example, the stress concentration factor for the simplified ductile hinge geometry of
The stress concentration factors are generally useful only in the linear elastic range. Stress concentration patterns for a number of other geometries can be determined through photoelastic measurements and other experimental methods. Stent designs based on the use of stress/strain concentration features, or ductile hinges, generally involve more complex hinge geometries and operate in the non-linear elastic and plastic deformation regimes.
The general nature of the relationship among applied forces, material properties, and ductile hinge geometry can be more easily understood through analysis of an idealized hinge 66 as shown in
Where b corresponds to the cylindrical tube wall thickness, h is the circumferential width of the ductile hinge, and δyp is the yield stress of the hinge material. Assuming only that expansion pressure is proportional to the plastic moment, it can be seen that the required expansion pressure to expand the tissue supporting device increases linearly with wall thickness b and as the square of ductile hinge width h. It is thus possible to compensate for relatively large changes in wall thickness b with relatively small changes in hinge width h. While the above idealized case is only approximate, empirical measurements of expansion forces for different hinge widths in several different ductile hinge geometries have confirmed the general form of this relationship. Accordingly, for different ductile hinge geometries it is possible to increase the thickness of the tissue supporting device to achieve radiopacity while compensating for the increased thickness with a much smaller decrease in hinge width.
Ideally, the stent wall thickness b should be as in as possible while still providing good visibility on a fluoroscope. For most stent materials, including stainless steel, this would suggest a thickness of about 0.005-0.007 inches (0.127-0.178 mm) or greater. The inclusion of ductile hinges in a stent design can lower expansion forces/pressures to very low levels for any material thickness of interest. Thus ductile hinges allow the construction of optimal wall thickness tissue supporting devices at expansion force levels significantly lower than current non-visible designs.
The expansion forces required to expand the tissue supporting device 20 according to the present invention from an initial condition illustrated in
Many tissue supporting devices fashioned from cylindrical tubes comprise networks of long, narrow, prismatic beams of essentially rectangular cross section as shown in
Where: E=Modulus of Elasticity
By contrast, in a ductile hinge based design according to the present invention, only the hinge itself deforms during expansion. The typical ductile hinge 32 is not a long narrow beam as are the struts in the known stents. Wall thickness of the present invention may be increased to 0.005 inches (0.127 mm) or greater, while hinge width is typically 0.002-0.003 inches (0.0508-0.0762 mm), preferably 0.0025 inches (0.0635 mm) or less. Typical hinge length, at 0.002 to 0.005 inches (0.0508-0.0127 mm), is more than an order of magnitude less than typical strut length. Thus, the ratio of b:h in a typical ductile hinge 32 is 2:1 or greater. This is an inherently stable ratio, meaning that the plastic moment for such a ductile hinge beam is much lower than the critical buckling moment Mcrit, and the ductile hinge beam deforms through normal strain-curvature. Ductile hinges 32 are thus not vulnerable to buckling when subjected to bending moments during expansion of the tissue supporting device 20.
To provide optimal recoil and crush-strength properties, it is desirable to design the ductile hinges so that relatively large strains, and thus large curvatures, are imparted to the hinge during expansion of the tissue supporting device. Curvature is defined as the reciprocal of the radius of curvature of the neutral axis of a beam in pure bending. A larger curvature during expansion results in the elastic curvature of the hinge being a small fraction of the total hinge curvature. Thus, the gross elastic recoil of the tissue supporting device is a small fraction of the total change in circumference. It is generally possible to do his because common stent materials, such as 316L Stainless Steel have very large elongations-to-failure (i.e., they are very ductile).
It is not practical to derive exact expressions for residual curvatures for complex hinge geometries and real materials (i.e., materials with non-idealized stress/strain curves). The general nature of residual curvatures and recoil of a ductile hinge may be understood by examining the moment curvature relationship for the elastic-ideally-plastic rectangular hinge 66 shown in
This function is plotted in
Imparting additional curvature in the plastic zone cannot further increase the elastic curvature, but will decrease the ratio of elastic to plastic curvature. Thus, additional curvature or larger expansion of the tissue supporting device will reduce the percentage recoil of the overall stunt structure.
As shown in
Where strain at the yield point is an independent material property (yield stress divided by elastic modulus); L is the length of the ductile hinge; and h is the width of the hinge. For non-idealized ductile hinges made of real materials, the constant 3 in the above expression is replaced by a slowly rising function of total strain, but the effect of geometry would remain the same. Specifically, the elastic rebound angle of a ductile hinge decreases as the hinge width h increases, and increases as the hinge length L increases. To minimize recoil, therefore, hinge width h should be increased and length L should be decreased.
Ductile hinge width h will generally be determined by expansion force criteria, so it is important to reduce hinge length to a practical minimum in order to minimize elastic rebound. Empirical data on recoil for ductile hinges of different lengths show significantly lower recoil for shorter hinge lengths, in good agreement with the above analysis.
The ductile hinges 32 of the tissue supporting device 20 provide a second important advantage in minimizing device recoil. The embodiment of
ΔC=RΔθ cos θ
Since elastic rebound of hinge curvature is nearly constant at any gross curvature, the net contribution to circumferential recoil ΔC is lower at higher strut angles θ. The final device circumference is usually specified as some fixed value, so decreasing overall strut length can increase the final strut angle θ. Total stent recoil can thus be minimized with ductile hinges by using shorter struts and higher hinge curvatures when expanded.
Empirical measurements have shown that tissue supporting device designs based on ductile hinges, such as the embodiment of
According to one example of the tissue supporting device of the invention, the device can be expanded by application of an internal pressure of about 2 atmospheres or less, and once expanded to a diameter between 2 and 3 times the initial diameter can withstand a compressive force of about 16 to 20 gm/mm or greater. Examples of typical compression force values for prior art devices are 3.8 to 4.0 gm/mm.
While both recoil and crush strength properties of tissue supporting devices can be improved by use of ductile hinges with large curvatures in the expanded configuration, care must be taken not to exceed an acceptable maximum strain level for the material being used. For the ductile hinge 44 of
Where εmax is maximum strain, h is ductile hinge width, L is ductile hinge length and θ is bend angle in radians. When strain, hinge width and bend angle are determined through other criteria, this expression can be evaluated to determine the correct ductile hinge length L.
For example, suppose the ductile hinge 44 of
Similar expressions may be developed to determine required lengths for more complicated ductile hinge geometries, such as shown in
In many designs of the prior art, circumferential expansion was accompanied by a significant contraction of the axial length of the stent which may be up to 15% of the initial device length. Excessive axial contraction can cause a number of problems in device deployment and performance including difficulty in proper placement and tissue damage. Designs based on ductile hinges 32 can minimize the axial contraction, or foreshortening, of a tissue supporting device during expansion as follows.
a and 9b illustrate an exaggerated ductile hinge 32 and shortened struts 28 in initial and expanded conditions. Each strut 28 is attached to two ductile hinges 32 at opposite ends. Each ductile hinge 32 has an instant center of rotation C1, C2 that is an effective pivot point for the attached strut 28. Initially, during expansion the pivot point C1 is displaced vertically by a distance d until C1 is positioned even with C2 as shown in
This ability to control axial contraction based on hinge and strut design provides great design flexibility when using ductile hinges. For example, a stent could be designed with zero axial contraction.
An alternative embodiment that illustrates the trade off between crush strength and axial contraction is shown in
According to one example of the present invention, the struts 72 are positioned initially at an angle of about 0° to 45° with respect to a longitudinal axis of the device. As the device is expanded radially from the unexpanded state illustrated in
According to one alternative embodiment of the present invention, the expandable tissue supporting device can also be used as a delivery device for certain beneficial agents including drugs, chemotherapy, or other agents. Due to the structure of the tissue supporting device incorporating ductile hinges, the widths of the struts can be substantially larger than the struts of the prior art devices. The struts due to their large size can be used for beneficial agent delivery by providing beneficial agent on the struts or within the struts. Examples of beneficial agent delivery mechanisms include coatings on the struts, such as polymer coatings containing beneficial agents, laser drilled holes in the struts containing beneficial agent, and the like.
Referring to
While the invention has been described in detail with reference to the preferred embodiments thereof, it will be apparent to one skilled in the art that various changes and modifications can be made and equivalents employed, without departing from the present invention.
This application is a continuation of prior application Ser. No. 11/837,416, filed Aug. 10, 2007 now abandoned which is a continuation of application Ser. No. 10/726,605 filed Dec. 4, 2003, now U.S. Pat. No. 7,279,004; which is a continuation of application Ser. No. 10/231,007 filed Aug. 30, 2002, abandoned; which is a continuation of application Ser. No. 09/649,217 filed Aug. 28, 2000, now U.S. Pat. No. 6,562,065; which is a continuation of application Ser. No. 09/183,555 filed Oct. 29, 1998, now U.S. Pat. No. 6,241,762; which claims priority from Provisional Application No. 60/079,881 filed Mar. 30, 1998, now expired, the entire contents of each such application incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
3657744 | Ersek | Apr 1972 | A |
4300244 | Bokros | Nov 1981 | A |
4531936 | Gordon | Jul 1985 | A |
4542025 | Tice et al. | Sep 1985 | A |
4580568 | Gianturco | Apr 1986 | A |
4650466 | Luther | Mar 1987 | A |
4733665 | Palmaz | Mar 1988 | A |
4739762 | Palmaz | Apr 1988 | A |
4776337 | Palmaz | Oct 1988 | A |
4800882 | Gianturco | Jan 1989 | A |
4824436 | Wolinsky | Apr 1989 | A |
4834755 | Silvestrini et al. | May 1989 | A |
4889119 | Jamiolkowski et al. | Dec 1989 | A |
4916193 | Tang et al. | Apr 1990 | A |
4955878 | See et al. | Sep 1990 | A |
4957508 | Kaneko et al. | Sep 1990 | A |
4960790 | Steela et al. | Oct 1990 | A |
4969458 | Wiktor | Nov 1990 | A |
4989601 | Marchosky et al. | Feb 1991 | A |
4990155 | Wilkoff et al. | Feb 1991 | A |
4994071 | MacGregor | Feb 1991 | A |
5017381 | Maruyama et al. | May 1991 | A |
5019090 | Pinchuk | May 1991 | A |
5049132 | Shaffer et al. | Sep 1991 | A |
5053048 | Pinchuk | Oct 1991 | A |
5059166 | Fischell et al. | Oct 1991 | A |
5059178 | Ya et al. | Oct 1991 | A |
5059211 | Stack et al. | Oct 1991 | A |
5078726 | Kreamer | Jan 1992 | A |
5085629 | Goldberg et al. | Feb 1992 | A |
5092841 | Spears | Mar 1992 | A |
5102417 | Palmaz | Apr 1992 | A |
5139480 | Hickle et al. | Aug 1992 | A |
5157049 | Haugwitz et al. | Oct 1992 | A |
5160341 | Brenneman et al. | Nov 1992 | A |
5171217 | March et al. | Dec 1992 | A |
5171262 | MacGregor | Dec 1992 | A |
5176617 | Fischell et al. | Jan 1993 | A |
5195984 | Schatz | Mar 1993 | A |
5197978 | Hess | Mar 1993 | A |
5213580 | Slepian et al. | May 1993 | A |
5223092 | Grinnell et al. | Jun 1993 | A |
5234456 | Silvestrini | Aug 1993 | A |
5242399 | Lau et al. | Sep 1993 | A |
5282823 | Schwartz et al. | Feb 1994 | A |
5283257 | Gregory et al. | Feb 1994 | A |
5286254 | Shapland et al. | Feb 1994 | A |
5288711 | Mitchell et al. | Feb 1994 | A |
5290271 | Jernberg | Mar 1994 | A |
5292512 | Schaefer et al. | Mar 1994 | A |
5304121 | Sahatjian | Apr 1994 | A |
5314688 | Kauffman et al. | May 1994 | A |
5342348 | Kaplan | Aug 1994 | A |
5342621 | Eury | Aug 1994 | A |
5344426 | Lau et al. | Sep 1994 | A |
5380299 | Fearnot et al. | Jan 1995 | A |
5383892 | Cardon et al. | Jan 1995 | A |
5383928 | Scott et al. | Jan 1995 | A |
5403858 | Bastard et al. | Apr 1995 | A |
5407683 | Shively | Apr 1995 | A |
5415869 | Straubinger et al. | May 1995 | A |
5419760 | Narciso, Jr. | May 1995 | A |
5439446 | Barry | Aug 1995 | A |
5439686 | Desai et al. | Aug 1995 | A |
5441515 | Khosravi et al. | Aug 1995 | A |
5441745 | Presant et al. | Aug 1995 | A |
5443458 | Eury | Aug 1995 | A |
5443496 | Schwartz et al. | Aug 1995 | A |
5443497 | Venbrux | Aug 1995 | A |
5443500 | Sigwart | Aug 1995 | A |
5447724 | Helmus et al. | Sep 1995 | A |
5449373 | Binchasik et al. | Sep 1995 | A |
5449382 | Dayton | Sep 1995 | A |
5449513 | Yokoyama et al. | Sep 1995 | A |
5457113 | Cullinan et al. | Oct 1995 | A |
5460817 | Langley et al. | Oct 1995 | A |
5462866 | Wang | Oct 1995 | A |
5464450 | Buscemi et al. | Nov 1995 | A |
5464650 | Berg et al. | Nov 1995 | A |
5472985 | Grainger et al. | Dec 1995 | A |
5473055 | Mongelli et al. | Dec 1995 | A |
5496365 | Sgro | Mar 1996 | A |
5499373 | Richards et al. | Mar 1996 | A |
5500013 | Buscemi et al. | Mar 1996 | A |
5510077 | Dinh et al. | Apr 1996 | A |
5512055 | Domb et al. | Apr 1996 | A |
5516781 | Morris et al. | May 1996 | A |
5523092 | Hanson et al. | Jun 1996 | A |
5527344 | Arzbaecher et al. | Jun 1996 | A |
5545210 | Hess | Aug 1996 | A |
5545569 | Grainger et al. | Aug 1996 | A |
5551954 | Buscemi et al. | Sep 1996 | A |
5554182 | Dinh et al. | Sep 1996 | A |
5556413 | Lam | Sep 1996 | A |
5562922 | Lambert | Oct 1996 | A |
5563146 | Morris et al. | Oct 1996 | A |
5571089 | Crocker | Nov 1996 | A |
5571166 | Dinh et al. | Nov 1996 | A |
5575771 | Walinsky | Nov 1996 | A |
5578075 | Dayton | Nov 1996 | A |
5591224 | Schwartz et al. | Jan 1997 | A |
5591227 | Dinh et al. | Jan 1997 | A |
5593434 | Williams | Jan 1997 | A |
5595722 | Grainger et al. | Jan 1997 | A |
5599352 | Dinh et al. | Feb 1997 | A |
5599722 | Grainger et al. | Feb 1997 | A |
5599844 | Grainger et al. | Feb 1997 | A |
5605696 | Eury et al. | Feb 1997 | A |
5607442 | Fischell et al. | Mar 1997 | A |
5607463 | Schwartz et al. | Mar 1997 | A |
5607475 | Cahalan et al. | Mar 1997 | A |
5609626 | Quijano | Mar 1997 | A |
5609629 | Fearnot et al. | Mar 1997 | A |
5616608 | Kinsella et al. | Apr 1997 | A |
5617878 | Taheri | Apr 1997 | A |
5618299 | Khosravi et al. | Apr 1997 | A |
5624411 | Tuch | Apr 1997 | A |
5628785 | Schwartz et al. | May 1997 | A |
5628787 | Mayer | May 1997 | A |
5629077 | Turnlund et al. | May 1997 | A |
5632840 | Campbell | May 1997 | A |
5637113 | Tartaglia et al. | Jun 1997 | A |
5643314 | Carpenter et al. | Jul 1997 | A |
5646160 | Morris et al. | Jul 1997 | A |
5649977 | Campbell | Jul 1997 | A |
5651174 | Schwartz et al. | Jul 1997 | A |
5660873 | Nikolaychik et al. | Aug 1997 | A |
5665591 | Sonenshein et al. | Sep 1997 | A |
5667764 | Kopia et al. | Sep 1997 | A |
5670161 | Healy et al. | Sep 1997 | A |
5670659 | Alas et al. | Sep 1997 | A |
5674241 | Bley et al. | Oct 1997 | A |
5674242 | Phan et al. | Oct 1997 | A |
5674278 | Boneau | Oct 1997 | A |
5679400 | Tuch | Oct 1997 | A |
5693085 | Buirge et al. | Dec 1997 | A |
5697967 | Dinh et al. | Dec 1997 | A |
5697971 | Fischell et al. | Dec 1997 | A |
5700286 | Tartaglia et al. | Dec 1997 | A |
5707385 | Williams | Jan 1998 | A |
5713949 | Jayaraman | Feb 1998 | A |
5716981 | Hunter et al. | Feb 1998 | A |
5722979 | Kusleika | Mar 1998 | A |
5725548 | Jayaraman | Mar 1998 | A |
5725549 | Lam | Mar 1998 | A |
5725567 | Wolff et al. | Mar 1998 | A |
5728150 | McDonald et al. | Mar 1998 | A |
5728420 | Keogh | Mar 1998 | A |
5733327 | Igaki et al. | Mar 1998 | A |
5733330 | Cox | Mar 1998 | A |
5733925 | Kunz et al. | Mar 1998 | A |
5735897 | Buirge | Apr 1998 | A |
5741293 | Wijay | Apr 1998 | A |
5744460 | Muller et al. | Apr 1998 | A |
5755772 | Evans et al. | May 1998 | A |
5759192 | Saunders | Jun 1998 | A |
5766239 | Cox | Jun 1998 | A |
5769883 | Buscemi et al. | Jun 1998 | A |
5770609 | Grainger et al. | Jun 1998 | A |
5773479 | Grainger et al. | Jun 1998 | A |
5776162 | Kleshinski | Jul 1998 | A |
5776181 | Lee et al. | Jul 1998 | A |
5776184 | Tuch | Jul 1998 | A |
5782908 | Cahalan et al. | Jul 1998 | A |
5788979 | Alt et al. | Aug 1998 | A |
5792106 | Mische | Aug 1998 | A |
5797898 | Santini et al. | Aug 1998 | A |
5799384 | Schwartz et al. | Sep 1998 | A |
5800507 | Schwartz | Sep 1998 | A |
5807404 | Richter | Sep 1998 | A |
5811447 | Kunz et al. | Sep 1998 | A |
5817152 | Birdsall et al. | Oct 1998 | A |
5820917 | Tuch | Oct 1998 | A |
5820918 | Ronan et al. | Oct 1998 | A |
5824045 | Alt | Oct 1998 | A |
5824048 | Tuch | Oct 1998 | A |
5824049 | Ragheb et al. | Oct 1998 | A |
5827322 | Williams | Oct 1998 | A |
5833651 | Donovan et al. | Nov 1998 | A |
5837008 | Berg et al. | Nov 1998 | A |
5837313 | Ding et al. | Nov 1998 | A |
5843117 | Alt et al. | Dec 1998 | A |
5843120 | Israel et al. | Dec 1998 | A |
5843166 | Lentz et al. | Dec 1998 | A |
5843172 | Yan | Dec 1998 | A |
5843175 | Frantzen | Dec 1998 | A |
5843741 | Wong et al. | Dec 1998 | A |
5849034 | Schwartz | Dec 1998 | A |
5851217 | Wolff et al. | Dec 1998 | A |
5851231 | Wolff et al. | Dec 1998 | A |
5853419 | Imran | Dec 1998 | A |
5855600 | Alt | Jan 1999 | A |
5865814 | Tuch | Feb 1999 | A |
5868781 | Killion | Feb 1999 | A |
5871535 | Wolff et al. | Feb 1999 | A |
5873904 | Ragheb et al. | Feb 1999 | A |
5876419 | Carpenter et al. | Mar 1999 | A |
5879697 | Ding et al. | Mar 1999 | A |
5882335 | Leone et al. | Mar 1999 | A |
5886026 | Hunter et al. | Mar 1999 | A |
5891108 | Leone et al. | Apr 1999 | A |
5893840 | Hull et al. | Apr 1999 | A |
5922020 | Klein et al. | Jul 1999 | A |
5922021 | Jang | Jul 1999 | A |
5928916 | Keogh | Jul 1999 | A |
5932243 | Fricker et al. | Aug 1999 | A |
5935506 | Schmitz et al. | Aug 1999 | A |
5945456 | Grainger et al. | Aug 1999 | A |
5957971 | Schwartz | Sep 1999 | A |
5964798 | Imran | Oct 1999 | A |
5968091 | Pinchuk et al. | Oct 1999 | A |
5968092 | Buscemi et al. | Oct 1999 | A |
5972027 | Johnson | Oct 1999 | A |
5976182 | Cox | Nov 1999 | A |
5980551 | Summers et al. | Nov 1999 | A |
5980972 | Ding | Nov 1999 | A |
5981568 | Kunz et al. | Nov 1999 | A |
5984957 | Laptewicz, Jr. et al. | Nov 1999 | A |
5992769 | Wise | Nov 1999 | A |
5994341 | Hunter et al. | Nov 1999 | A |
6007517 | Anderson | Dec 1999 | A |
6015432 | Rakos et al. | Jan 2000 | A |
6017362 | Lau | Jan 2000 | A |
6017363 | Hojeibane | Jan 2000 | A |
6019789 | Dinh et al. | Feb 2000 | A |
6022371 | Killion | Feb 2000 | A |
6024740 | Lesh et al. | Feb 2000 | A |
6027526 | Limon et al. | Feb 2000 | A |
6030414 | Taheri | Feb 2000 | A |
6042606 | Frantzen | Mar 2000 | A |
6056722 | Jayaraman | May 2000 | A |
6063101 | Jacobsen et al. | May 2000 | A |
6071305 | Brown et al. | Jun 2000 | A |
6074659 | Kunz et al. | Jun 2000 | A |
6083258 | Yadav | Jul 2000 | A |
6086582 | Altman et al. | Jul 2000 | A |
6087479 | Stamler et al. | Jul 2000 | A |
6096070 | Ragheb et al. | Aug 2000 | A |
6099561 | Alt | Aug 2000 | A |
6099562 | Ding et al. | Aug 2000 | A |
6117101 | Diederich et al. | Sep 2000 | A |
6120535 | McDonald et al. | Sep 2000 | A |
6120536 | Ding et al. | Sep 2000 | A |
6120847 | Yang et al. | Sep 2000 | A |
6121027 | Clapper et al. | Sep 2000 | A |
6123861 | Santini et al. | Sep 2000 | A |
6140127 | Sprague | Oct 2000 | A |
6153252 | Hossainy et al. | Nov 2000 | A |
6156062 | McGuinness | Dec 2000 | A |
6159488 | Nagler et al. | Dec 2000 | A |
6171609 | Kunz | Jan 2001 | B1 |
6174326 | Kitaoka et al. | Jan 2001 | B1 |
6193746 | Strecker | Feb 2001 | B1 |
6203569 | Wijay | Mar 2001 | B1 |
6206914 | Soykan et al. | Mar 2001 | B1 |
6206915 | Fagan et al. | Mar 2001 | B1 |
6206916 | Furst | Mar 2001 | B1 |
6231600 | Zhong | May 2001 | B1 |
6240616 | Yan | Jun 2001 | B1 |
6241762 | Shanley | Jun 2001 | B1 |
6245101 | Drasler et al. | Jun 2001 | B1 |
6249952 | Ding | Jun 2001 | B1 |
6254632 | Wu et al. | Jul 2001 | B1 |
6261318 | Lee et al. | Jul 2001 | B1 |
6268390 | Kunz | Jul 2001 | B1 |
6273908 | Ndondo-Lay | Aug 2001 | B1 |
6273911 | Cox et al. | Aug 2001 | B1 |
6273913 | Wright et al. | Aug 2001 | B1 |
6280411 | Lennox | Aug 2001 | B1 |
6287332 | Bolz et al. | Sep 2001 | B1 |
6290673 | Shanley | Sep 2001 | B1 |
6293967 | Shanley | Sep 2001 | B1 |
6299604 | Ragheb et al. | Oct 2001 | B1 |
6306166 | Barry et al. | Oct 2001 | B1 |
6306421 | Kunz et al. | Oct 2001 | B1 |
6309414 | Rolando et al. | Oct 2001 | B1 |
6312460 | Drasler et al. | Nov 2001 | B2 |
6358556 | Ding et al. | Mar 2002 | B1 |
6358989 | Kunz et al. | Mar 2002 | B1 |
6369039 | Palasis et al. | Apr 2002 | B1 |
6379381 | Hossainy et al. | Apr 2002 | B1 |
6387124 | Buscemi et al. | May 2002 | B1 |
6395326 | Castro et al. | May 2002 | B1 |
6399144 | Dinh et al. | Jun 2002 | B2 |
6403635 | Kinsella et al. | Jun 2002 | B1 |
6423092 | Datta et al. | Jul 2002 | B2 |
6423345 | Bernstein et al. | Jul 2002 | B2 |
6429232 | Kinsella et al. | Aug 2002 | B1 |
6451051 | Drasler et al. | Sep 2002 | B2 |
6468302 | Cox et al. | Oct 2002 | B2 |
6475237 | Drasler et al. | Nov 2002 | B2 |
6482810 | Brem et al. | Nov 2002 | B1 |
6491666 | Santini et al. | Dec 2002 | B1 |
6491938 | Kunz et al. | Dec 2002 | B2 |
6497916 | Taylor et al. | Dec 2002 | B1 |
6500859 | Kinsella et al. | Dec 2002 | B2 |
6506411 | Hunter et al. | Jan 2003 | B2 |
6506437 | Harish et al. | Jan 2003 | B1 |
6511505 | Cox et al. | Jan 2003 | B2 |
6515009 | Kunz et al. | Feb 2003 | B1 |
6528121 | Ona et al. | Mar 2003 | B2 |
6530951 | Bates et al. | Mar 2003 | B1 |
6533807 | Wolinsky et al. | Mar 2003 | B2 |
6537256 | Santini, Jr. et al. | Mar 2003 | B2 |
6540774 | Cox | Apr 2003 | B1 |
6544544 | Hunter et al. | Apr 2003 | B2 |
6551838 | Santini et al. | Apr 2003 | B2 |
6558733 | Hossainy et al. | May 2003 | B1 |
6562065 | Shanley | May 2003 | B1 |
6565602 | Rolando et al. | May 2003 | B2 |
6569441 | Kunz et al. | May 2003 | B2 |
6569688 | Sivan et al. | May 2003 | B2 |
6585764 | Wright et al. | Jul 2003 | B2 |
6585773 | Xie | Jul 2003 | B1 |
6599928 | Kunz et al. | Jul 2003 | B2 |
6602284 | Cox et al. | Aug 2003 | B2 |
6616690 | Rolando et al. | Sep 2003 | B2 |
6638302 | Curcio et al. | Oct 2003 | B1 |
6656162 | Santini et al. | Dec 2003 | B2 |
6656217 | Herzog, Jr. et al. | Dec 2003 | B1 |
6663881 | Kunz et al. | Dec 2003 | B2 |
6689390 | Bernstein et al. | Feb 2004 | B2 |
6706061 | Fischell et al. | Mar 2004 | B1 |
6720350 | Kunz et al. | Apr 2004 | B2 |
6730064 | Ragheb et al. | May 2004 | B2 |
6730116 | Wolinsky et al. | May 2004 | B1 |
6846841 | Hunter et al. | Jan 2005 | B2 |
6869443 | Buscemi et al. | Mar 2005 | B2 |
6890339 | Sahatjian et al. | May 2005 | B2 |
20010000802 | Soykan et al. | May 2001 | A1 |
20010027340 | Wright et al. | Oct 2001 | A1 |
20010029351 | Falotico et al. | Oct 2001 | A1 |
20010034363 | Li et al. | Oct 2001 | A1 |
20010044652 | Moore | Nov 2001 | A1 |
20020002400 | Drasler et al. | Jan 2002 | A1 |
20020005206 | Falotico et al. | Jan 2002 | A1 |
20020007209 | Scheerder et al. | Jan 2002 | A1 |
20020022876 | Richter et al. | Feb 2002 | A1 |
20020028243 | Masters | Mar 2002 | A1 |
20020032414 | Ragheb et al. | Mar 2002 | A1 |
20020038145 | Jang | Mar 2002 | A1 |
20020068969 | Shanley et al. | Jun 2002 | A1 |
20020072511 | New et al. | Jun 2002 | A1 |
20020082679 | Sirhan et al. | Jun 2002 | A1 |
20020082680 | Shanley et al. | Jun 2002 | A1 |
20020094985 | Hermann et al. | Jul 2002 | A1 |
20020123801 | Pacetti et al. | Sep 2002 | A1 |
20020142039 | Claude | Oct 2002 | A1 |
20020155212 | Hossainy | Oct 2002 | A1 |
20030028244 | Bates | Feb 2003 | A1 |
20030036794 | Ragheb et al. | Feb 2003 | A1 |
20030060877 | Falotico et al. | Mar 2003 | A1 |
20030068355 | Shanley et al. | Apr 2003 | A1 |
20030100865 | Santini et al. | May 2003 | A1 |
20030125803 | Vallana et al. | Jul 2003 | A1 |
20030176915 | Wright et al. | Sep 2003 | A1 |
20030199970 | Shanley | Oct 2003 | A1 |
20030216699 | Falotico | Nov 2003 | A1 |
20040122505 | Shanley | Jun 2004 | A1 |
20040122506 | Shanley et al. | Jun 2004 | A1 |
20040127976 | Diaz | Jul 2004 | A1 |
20040127977 | Shanley | Jul 2004 | A1 |
Number | Date | Country |
---|---|---|
2234787 | Apr 1998 | CA |
2323358 | Oct 1999 | CA |
2409787 | Dec 2001 | CA |
20200220 | Apr 2002 | DE |
0294905 | Dec 1988 | EP |
0374698 | Dec 1989 | EP |
0470569 | Feb 1992 | EP |
0335341 | Apr 1992 | EP |
0567816 | Apr 1993 | EP |
0 540 290 | May 1993 | EP |
0543653 | May 1993 | EP |
0375520 | Jul 1993 | EP |
0551182 | Jul 1993 | EP |
0566245 | Oct 1993 | EP |
0568310 | Nov 1993 | EP |
0604022 | Jun 1994 | EP |
0623354 | Nov 1994 | EP |
0470246 | Jun 1995 | EP |
0711158 | May 1996 | EP |
0712615 | May 1996 | EP |
0716836 | Jun 1996 | EP |
0 734 698 | Oct 1996 | EP |
0752885 | Jan 1997 | EP |
0761251 | Mar 1997 | EP |
0566807 | Jun 1997 | EP |
0706376 | Jun 1997 | EP |
0797963 | Oct 1997 | EP |
0809515 | Dec 1997 | EP |
0832655 | Apr 1998 | EP |
0 850 604 | Jul 1998 | EP |
0850651 | Jul 1998 | EP |
0 875 218 | Nov 1998 | EP |
0 887 051 | Dec 1998 | EP |
0627226 | Dec 1998 | EP |
0679373 | Jan 1999 | EP |
0566245 | Jun 1999 | EP |
0934036 | Aug 1999 | EP |
0938878 | Sep 1999 | EP |
0 950 386 | Oct 1999 | EP |
0959812 | Dec 1999 | EP |
0980280 | Feb 2000 | EP |
1132058 | Sep 2001 | EP |
1172074 | Jan 2002 | EP |
1 181 943 | Feb 2002 | EP |
1189554 | Mar 2002 | EP |
0897700 | Jul 2002 | EP |
1 236 478 | Sep 2002 | EP |
0747069 | Sep 2002 | EP |
0770401 | Nov 2002 | EP |
1348402 | Oct 2003 | EP |
0824902 | Nov 2004 | EP |
1570807 | Sep 2005 | EP |
1118325 | Jan 2006 | EP |
1222941 | May 2006 | EP |
1277449 | Jun 2006 | EP |
1 772 114 | Apr 2007 | EP |
1223305 | Apr 2008 | EP |
2 683 449 | May 1993 | FR |
2 764 794 | Dec 1998 | FR |
9001969 | Mar 1990 | WO |
WO 9013332 | Nov 1990 | WO |
WO 9110424 | Jul 1991 | WO |
WO 9111193 | Aug 1991 | WO |
WO 9112779 | Sep 1991 | WO |
9117789 | Nov 1991 | WO |
9200747 | Jan 1992 | WO |
WO 9212717 | Aug 1992 | WO |
WO 9215286 | Sep 1992 | WO |
WO 9306792 | Apr 1993 | WO |
9311120 | Jun 1993 | WO |
9407529 | Apr 1994 | WO |
9413268 | Jun 1994 | WO |
WO 9421308 | Sep 1994 | WO |
9424962 | Nov 1994 | WO |
WO 9424961 | Nov 1994 | WO |
9503796 | Feb 1995 | WO |
WO 9503036 | Feb 1995 | WO |
WO 9503795 | Feb 1995 | WO |
WO 9625176 | Aug 1995 | WO |
WO 9524908 | Sep 1995 | WO |
9534255 | Dec 1995 | WO |
9603092 | Feb 1996 | WO |
WO 9629028 | Sep 1996 | WO |
9632907 | Oct 1996 | WO |
WO 9704721 | Feb 1997 | WO |
9710011 | Mar 1997 | WO |
9733534 | Sep 1997 | WO |
9740783 | Nov 1997 | WO |
WO 9805270 | Feb 1998 | WO |
WO 9806092 | Feb 1998 | WO |
WO 9808566 | Mar 1998 | WO |
WO 9818407 | May 1998 | WO |
WO 9819628 | May 1998 | WO |
9823228 | Jun 1998 | WO |
WO 9823244 | Jun 1998 | WO |
9834669 | Aug 1998 | WO |
WO 9836784 | Aug 1998 | WO |
9847447 | Oct 1998 | WO |
9856312 | Dec 1998 | WO |
WO 9858600 | Dec 1998 | WO |
WO 9915108 | Apr 1999 | WO |
WO 9916386 | Apr 1999 | WO |
WO 9916477 | Apr 1999 | WO |
9936002 | Jul 1999 | WO |
9939661 | Aug 1999 | WO |
WO 9944536 | Sep 1999 | WO |
9949810 | Oct 1999 | WO |
WO 9949928 | Oct 1999 | WO |
9955395 | Nov 1999 | WO |
WO 9955396 | Nov 1999 | WO |
WO 0010613 | Mar 2000 | WO |
WO 0010622 | Mar 2000 | WO |
0021584 | Apr 2000 | WO |
0027445 | May 2000 | WO |
0032255 | Jun 2000 | WO |
0040278 | Jul 2000 | WO |
0045744 | Aug 2000 | WO |
WO 0069368 | Nov 2000 | WO |
WO 0071054 | Nov 2000 | WO |
WO 0117577 | Mar 2001 | WO |
WO 0145763 | Jun 2001 | WO |
WO 0145862 | Jun 2001 | WO |
0152915 | Jul 2001 | WO |
WO 0149338 | Jul 2001 | WO |
0187342 | Nov 2001 | WO |
WO 0187376 | Nov 2001 | WO |
WO 0193781 | Dec 2001 | WO |
WO 0217880 | Mar 2002 | WO |
0226162 | Apr 2002 | WO |
WO 0226281 | Apr 2002 | WO |
0241931 | May 2002 | WO |
WO 02060506 | Aug 2002 | WO |
02087586 | Nov 2002 | WO |
WO 03007842 | Jan 2003 | WO |
03018083 | Mar 2003 | WO |
WO 03047463 | Jun 2003 | WO |
03057218 | Jul 2003 | WO |
WO 2004043510 | May 2004 | WO |
WO 2004043511 | May 2004 | WO |
2005053937 | Jun 2005 | WO |
2005118971 | Dec 2005 | WO |
2006036319 | Apr 2006 | WO |
Number | Date | Country | |
---|---|---|---|
20080249609 A1 | Oct 2008 | US |
Number | Date | Country | |
---|---|---|---|
60079881 | Mar 1998 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11837416 | Aug 2007 | US |
Child | 12139737 | US | |
Parent | 10726605 | Dec 2003 | US |
Child | 11837416 | US | |
Parent | 10231007 | Aug 2002 | US |
Child | 10726605 | US | |
Parent | 09649217 | Aug 2000 | US |
Child | 10231007 | US | |
Parent | 09183555 | Oct 1998 | US |
Child | 09649217 | US |